Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
To determine if Neu is dominant over transforming growth factor beta (TGF-beta), we crossed mouse mammary tumor virus (MMTV)-Neu mice with MMTV-TGF-beta1(S223/225) mice expressing active TGF-beta1 in the mammary gland. Bigenic (NT) and Neu-induced mammary tumors developed with a similar latency. The bigenic tumors and their metastases were less proliferative than those occurring in MMTV-Neu mice. However, NT tumors exhibited less apoptosis and were more locally invasive and of higher histological grade. NT mice exhibited more circulating tumor cells and lung metastases than Neu mice, while NT tumors contained higher levels of phosphorylated (active) Smad2, Akt, mitogen-activated protein kinase (MAPK), and p38, as well as vimentin content and Rac1 activity in situ than tumors expressing Neu alone. Ex vivo, NT cells exhibited higher levels of P-Akt and P-MAPK than Neu cells. These were inhibited by the TGF-beta inhibitor-soluble TGF-beta type II receptor (TbetaRII:Fc), suggesting they were activated by autocrine TGF-beta. TGF-beta stimulated migration of Neu cells into surrounding matrix, while the soluble TGF-beta inhibitor abrogated motility and invasiveness of NT cells. These data suggest that (i) the antimitogenic and prometastatic effects of TGF-beta can exist simultaneously and (ii) Neu does not abrogate TGF-beta-mediated antiproliferative action but can synergize with TGF-beta in accelerating metastatic tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 1×
“Because of the ability of Neu to signal with increased potency to Ras/MAPK ( 52 ), we speculated that overexpression of Neu may prevent TGF--mediated growth inhibition and potentially accelerate Neu-induced tumors.”
BackgroundMissing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Cited by
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
“The expression of activated a TGFBRI transgene in mouse mammary tumors driven by ErbB2/HER2 oncogenes enhanced metastasis of these tumors to the lungs (Muraoka et al., 2003; Siegel et al., 2003).”
BackgroundTGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
Self-citationSignaling cross-talk between TGF-β/BMP and other pathways
Guo, X., & Wang, X.-F. (2009) · Cell Research · doi:10.1038/cr.2008.302 · Cited by 1,015
Modelling glandular epithelial cancers in three-dimensional cultures
Debnath, J., & Brugge, J. S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1695 · Cited by 1,015
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918
“However, others have shown that enhancement of TGFb signaling by expression of a constitutively active TGFb1 (Muraoka et al., 2003; Muraoka- Cook et al., 2004) or TbRI (Muraoka-Cook et al., 2004, 2006; Siegel et al., 2003) in mammary epithelial cells in conjunction with c-Neu of PyVmT expression…”
BackgroundResultInfluentialSelf-citation
Metadata
- Authors
- Muraoka, R. S., Koh, Y., Roebuck, L. R., Sanders, M. E., Brantley-Sieders, D., Gorska, A. E., Moses, H. L., & Arteaga, C. L.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2003-12-01
- Volume
- 23
- Issue
- 23
- Pages
- 8691-8703
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2163032998
- Cited by
- 191
- References
- 3
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.